4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
Clinical trial NCT04637503 · RECRUITING
Trial details
- NCT number
- NCT04637503
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2029-12-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.